AVANIR Pharmaceuticals (AVANIR) is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Companys product candidates address therapeutic markets that include the central nervous system, inflammatory diseases and infectious diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). AVANIRs first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA). AVANIR entered into an agreement in July 2007, to sell FazaClo to Azur Pharma, Inc. (Azur). The sale was closed on August 3, 2007.